Rheumatic and musculoskeletal disease information
| Primary RMD diagnosis | Inflammatory RMDs | 4604 (90) |
| Inflammatory joint diseases | 2979 (58) | |
| Rheumatoid arthritis | 1686 (33) | |
| Axial spondyloarthritis (including ankylosing spondylitis) | 573 (11) | |
| Psoriatic arthritis | 505 (10) | |
| Other peripheral spondyloarthritis (including reactive arthritis) | 114 (2) | |
| Juvenile idiopathic arthritis, not systemic | 23 (<1) | |
| Systemic juvenile idiopathic arthritis | 7 (<1) | |
| Other inflammatory arthritis | 70 (1) | |
| Connective tissue diseases | 928 (18) | |
| Systemic lupus erythematosus | 367 (7) | |
| Primary anti-phospholipid syndrome | 26 (1) | |
| Sjogren's syndrome | 223 (4) | |
| Systemic sclerosis | 162 (3) | |
| Idiopathic inflammatory myopathy (myositis) | 69 (1) | |
| Mixed connective tissue disease | 37 (1) | |
| Undifferentiated connective tissue disease | 43 (1) | |
| Ehlers-Danlos syndromes | 1 (<1) | |
| Vasculitis | 593 (12) | |
| Large vessel vasculitis – Takayasu arteritis | 14 (<1) | |
| Large vessel vasculitis – giant cell arteritis | 141 (3) | |
| Polymyalgia rheumatica | 239 (5) | |
| Medium-vessel vasculitis (polyarteritis nodosa, Kawasaki disease) | 11 (<1) | |
| ANCA-associated vasculitis (MP, GPA, EGPA) | 127 (2) | |
| Immune complex small vessel vasculitis | 7 (<1) | |
| Behcet's syndrome | 33 (1) | |
| Other vasculitis | 21 (<1) | |
| Other immune-mediated inflammatory diseases | 106 (2) | |
| Monogenic autoinflammatory syndrome | 13 (<1) | |
| Non-monogenic autoinflammatory syndrome | 12 (<1) | |
| IgG4-related disease | 16 (<1) | |
| Sarcoidosis | 56 (1) | |
| Relapsing polychondritis | 7 (<1) | |
| Chronic recurrent multifocal osteomyelitis | 2 (<1) | |
| Non-inflammatory RMDs | 517 (10) | |
| Gout or other crystal arthritis | 62 (1) | |
| Osteoporosis | 112 (2) | |
| Osteoarthritis | 240 (5) | |
| Fibromyalgia | 36 (1) | |
| Chronic mechanical back pain | 16 (<1) | |
| Radiculopathy or regional pain | 7 (<1) | |
| Other mechanical RMD (eg, tendinitis and bursitis) | 44 (1) | |
| Rheumatic disease activity (only applicable to patients with inflammatory RMD; n=4604) | Remission or inactive disease | 1867 (41) |
| Minimal or low disease activity | 1276 (28) | |
| Moderate disease activity | 610 (13) | |
| Severe or high disease activity | 76 (2) | |
| Missing/unknown | 775 (17) | |
| Medication exposure at the time of vaccination (only applicable to patients with inflammatory RMD; n=4604) | csDMARDS | 2497 (54) |
| Antimalarials (including hydroxychloroquine and chloroquine) | 568 (12) | |
| Held before vaccination | 2 | |
| Reduced before vaccination | 1 | |
| Held after vaccination | 3 | |
| Reduced after vaccination | 2 | |
| Leflunomide | 211 (5) | |
| Held before vaccination | 7 | |
| Reduced before vaccination | 1 | |
| Held after vaccination | 2 | |
| Methotrexate | 1557 | |
| Held before vaccination | 58 | |
| Reduced before vaccination | 3 | |
| Held after vaccination | 90 | |
| Reduced after vaccination | 1 | |
| Sulfasalazine | 161 (4) | |
| Held before vaccination | 1 | |
| Held after vaccination | 1 | |
| Reduced after vaccination | 1 | |
| bDMARDS | 1944 (42) | |
| Abatacept | 103 (2) | |
| Held before vaccination | 5 | |
| Held after vaccination | 3 | |
| Belimumab | 32 (1) | |
| Held before vaccination | 2 | |
| Rituximab | 260 (6) | |
| Held before vaccination | 18 | |
| Reduced before vaccination | 2 | |
| Held after vaccination | 1 | |
| Reduced after vaccination | 1 | |
| IL-1 inhibitors (including anakinra, canakinumab, rilonacept) | 19 (<1) | |
| IL-6 inhibitors (including tocilizumab and sarilumab) | 222 (5) | |
| Held before vaccination | 16 | |
| Held after vaccination | 4 | |
| Reduced after vaccination | 1 | |
| IL-12/23 inhibitors (including ustekinumab) | 34 (1) | |
| Held before vaccination | 2 | |
| IL-23 inhibitors (guselkumab, risankizumab and tildrakizumab) | 2 (<1) | |
| IL-17 inhibitors (including secukinumab, ixekizumab and brodalumab) | 99 (2) | |
| Held before vaccination | 4 | |
| Held after vaccination | 4 | |
| Reduced after vaccination | 1 | |
| TNF-inhibitors (including adalimumab, certolizumab, etanercept, golimumab, infliximab and biosimilars) | 1173 (25) | |
| Held before vaccination | 67 | |
| Reduced before vaccination | 5 | |
| Held after vaccination | 29 | |
| Reduced after vaccination | 2 | |
| tsDMARDS | 175 (4) | |
| Apremilast | 13 (<1) | |
| JAK inhibitors (including tofacitinib, baricitinib and upadacitinib) | 162 (4) | |
| Held before vaccination | 5 | |
| Reduced before vaccination | 1 | |
| Held after vaccination | 10 | |
| Immunosuppressants | 1621 (35) | |
| Glucocorticoids (systemic) | 1385 (30) | |
| Held before vaccination | 6 | |
| Reduced before vaccination | 6 | |
| Held after vaccination | 6 | |
| Reduced after vaccination | 9 | |
| Azathioprine/6-mercaptopurine | 88 (2) | |
| Held before vaccination | 2 | |
| Cyclosporine | 15 (<1) | |
| Held before vaccination | 2 | |
| Reduced before vaccination | 1 | |
| Cyclophosphamide | 8 (<1) | |
| Mycophenolate mofetil/mycophenolic acid | 123 (3) | |
| Held before vaccination | 6 | |
| Held after vaccination | 2 | |
| Reduced after vaccination | 1 | |
| Tacrolimus | 2 (<1) | |
| Other | 78 (2) | |
| Intravenous immunoglobulin | 15 (<1) | |
| Held after vaccination | 1 | |
| Antifibrotics (pirfenidone and nintedanib) | 5 (<1) | |
| Thalidomide/lenalidomide | 2 (<1) | |
| Colchicine | 24 (<1) | |
| Denosumab | 26 (1) | |
| Mepolizumab | 4 (<1) | |
| Pembrolizumab | 1 (<1) | |
| Vedolizumab | 1 (<1) | |
| Unknown/missing | 43 (1) | |
| None | 393 (9) |
All values are n (%) unless stated otherwise.
ANCA, anti-neutrophil cytoplasmic antibody; bDMARDs, biological disease-modifying antirheumatic drugs; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; EGPA, eosinophilic granulomatosis with polyangiitis; GPA, granulomatosis with polyangiitis; IL, interleukin; JAK, Janus kinase; MP, microscopic polyangiitis; TNF, tumour necrosis factor; tsDMARDs, targeted synthetic disease-modifying antirheumatic drug.